HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Human immunodeficiency virus 1 p16 protease

Subscribe to New Research on Human immunodeficiency virus 1 p16 protease

Also Known As:

p16 protease, Human immunodeficiency virus 1; HIV-1 protease; p16 pol gene product, HIV-1; p16 pol gene product, Human immunodeficiency virus 1; p16 pol gene product, human immunodeficiency virus type 1; p16 protease, HIV-1

Networked: 206 relevant articles (5 outcomes, 16 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Weber, Irene T: 6 articles (07/2013 - 05/2006)
2.	Kovalevsky, Andrey Y: 5 articles (07/2013 - 05/2006)
3.	Hosur, M V: 5 articles (11/2009 - 06/2002)
4.	Prashar, Vishal: 5 articles (11/2009 - 07/2005)
5.	Schiffer, Celia A: 4 articles (02/2015 - 03/2002)
6.	Ghosh, Arun K: 4 articles (07/2014 - 10/2006)
7.	Das, Amit: 4 articles (11/2009 - 12/2006)
8.	Ikezoe, Takayuki: 4 articles (08/2006 - 04/2004)
9.	Yang, Yang: 4 articles (08/2006 - 04/2004)
10.	Koeffler, H Phillip: 4 articles (08/2006 - 04/2004)

Related Diseases

1.	Acquired Immunodeficiency Syndrome (AIDS) 12/01/2009 - "Antiviral inhibitors of HIV-1 protease are a notable success of structure-based drug design and have dramatically improved AIDS therapy. " 01/01/2005 - "HIV-1 protease inhibitors had an immediate and dramatic impact on the outcome of HIV/AIDS when launched in late 1995, and the search for new and improved next generation molecules has been under way in many laboratories. " 12/01/2015 - "Several studies have focused on HIV-1 protease for developing drugs for treating AIDS. " 02/01/2015 - "Overall, this study aids in the understanding of the structural dynamics basis of drug resistance and evolutionary optimization in the HIV-1 protease system. " 08/01/2010 - "In a randomized trial, AIDS Clinical Trials Group (ACTG) protocol 5146 (A5146) investigated the use of therapeutic drug monitoring (TDM) to adjust doses of HIV-1 protease inhibitors (PIs) in patients with prior virologic failure on PI-based therapy who were starting a new PI-based regimen. "
2.	Infection 12/01/2015 - "This is the first time that HIV-1 protease expression, not whole virus infection of the cell, was observed to trigger the apoptotic pathway, including caspse-3 activation. " 06/13/2014 - "HIV-1 protease is an essential enzyme for viral particle maturation and is a target in the fight against HIV-1 infection worldwide. " 01/01/2014 - " of multiple infections was done using a previously published RFLP assay for the HIV-1 protease gene, which is able of distinguishing between infections caused by a single or multiple HIV-1 subtypes. " 01/01/2014 - "Analysis of HIV-1 protease gene reveals frequent multiple infections followed by recombination among drug treated individuals living in São Paulo and Santos, Brazil." 11/01/2011 - "Analysis of replicating viruses from a single round of infection identified 50 amino acid substitutions at 35 HIV-1 protease residue positions. "
3.	HIV Infections (HIV Infection) 01/01/2014 - "The dynamics of HIV-1 protease (HIV-pr), a drug target for HIV infection, has been studied extensively by both computational and experimental methods. " 05/15/2008 - "HIV-1 protease has been an important drug target for the antiretroviral treatment of HIV infection. " 01/01/2003 - "We studied factors associated with treatment adherence in 88 male and 21 female adults (age range, 24-65 years) with HIV infection undergoing therapy with HIV-1 protease inhibitors (PIs) in Italy. " 01/01/2005 - "The efficacy of HIV-1 protease inhibitors (PIs) as part of highly active antiretroviral therapy is now well established and has provided benefits to many patients with HIV infection. " 03/25/2008 - "HIV-1 protease is a key target in treating HIV infection and AIDS, with 10 inhibitors used clinically. "
4.	HTLV-I Infections (HTLV-I Infection) 12/15/1998 - "The data suggested that the substrate binding site of HTLV-I protease is different from the substrate binding sites of pepsin and HIV-1 protease, and that currently employed HIV-1 protease inhibitors would not be effective for the treatment of HTLV-I infections."
5.	Lipodystrophy 02/01/2000 - "The study group consisted of 14 consecutive HIV-infected patients receiving treatment with HIV-1 protease inhibitors, who experienced partial lipodystrophy. " 05/01/2011 - "There are limited reports regarding the role of reconstructive procedures to address the physical defects imposed by the various lipodystrophy syndromes, and much of the work to date has focused around facial lipoatrophy in patients with HIV-1 protease inhibitor induced disease. " 10/01/2002 - "In vitro evidence of inhibition of mitochondrial protease processing by HIV-1 protease inhibitors in yeast: a possible contribution to lipodystrophy syndrome." 11/20/2001 - "Long-term use of HIV-1 protease inhibitors (PIs) is associated with a lipodystrophy syndrome. " 02/01/2000 - "Patients infected with the human immunodeficiency virus (HIV) who are receiving therapy that includes HIV-1 protease inhibitors have been reported to develop a lipodystrophy characterized by loss of subcutaneous fat from the extremities and face but excess fat deposition in the neck and trunk. "

Related Drugs and Biologics

1.	Enzymes
2.	Pepsin A (Pepsin)
3.	Ritonavir (Norvir)
4.	Nelfinavir (Viracept)
5.	Proteins (Proteins, Gene)
6.	Nevirapine (Viramune)
7.	Cholic Acid
8.	Lamivudine (3TC)
9.	Transferases
10.	kynostatin 272

Related Therapies and Procedures

1.	Highly Active Antiretroviral Therapy (HAART)
2.	Therapeutics
3.	Immunotherapy
4.	Art Therapy